{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T08:06:29Z","timestamp":1789632389269,"version":"build-2803163510"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>We sought to investigate the effect PUL has on pre-operative irritative voiding symptoms in patients presenting for HoLEP, and if this leads to different post-operative outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a single-institution retrospective analysis of our prospective HoLEP registry. Propensity score matching of prostate size and history of urinary retention was used to match the patients who had prior PUL with patients without prior benign prostatic hyperplasia (BPH) surgery 1:2. We analyzed baseline demographics, operative details, post-operative outcomes, and pre-operative\/post-operative International Prostate Symptom Score (IPSS) and Michigan Incontinence Symptom Index (MISI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 2114 patients who underwent HoLEP, 1242 had sufficient data. There were 59 patients who had a HoLEP after prior PUL and a control cohort was made consisting of 118 patients. At baseline, the control group had more alpha blocker use (69% vs 54% (\n                      <jats:italic>p<\/jats:italic>\n                      =0.05)) and higher American Association of Anesthesia scores. Enucleation efficiency was similar between groups (1.82 vs 1.94 g\/min (\n                      <jats:italic>p<\/jats:italic>\n                      =0.634)) but morcellation efficiency was lower in the PUL arm (9.8 vs 7.2 g\/min (\n                      <jats:italic>p<\/jats:italic>\n                      &lt;0.001)). More patients in the PUL cohort required anti-cholinergics and beta-3 agonists post-operatively (8.5% vs 19%,\n                      <jats:italic>p<\/jats:italic>\n                      =0.084). With regards to symptom scores, pre-operative MISI severity scores were significantly higher in the PUL group (median 6 vs 3 (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.011)) and no other differences were noted.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Patients presenting for HoLEP after prior PUL have significantly higher MISI severity scores. This does not translate to differences in post-operative outcomes compared to those who had HoLEP as their first BPH surgery.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11255-026-05150-z","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T15:54:05Z","timestamp":1777910045000},"page":"4103-4108","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Holmium laser enucleation of the prostate after prostatic urethral lift: the state of bother"],"prefix":"10.1007","volume":"58","author":[{"given":"Amir","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny N","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perry","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allaa","family":"Fadl-Alla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Krambeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"key":"5150_CR1","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1097\/UPJ.0000000000000691","volume":"12","author":"HV Patel","year":"2025","unstructured":"Patel HV, Breyer BN, Jones C (2025) Contemporary trends of benign prostatic hyperplasia procedures in the AUA quality registry: are we moving the needle toward more minimally invasive treatments? Urol Pract 12:124\u2013129. https:\/\/doi.org\/10.1097\/UPJ.0000000000000691","journal-title":"Urol Pract"},{"key":"5150_CR2","first-page":"8802","volume":"24","author":"CG Roehrborn","year":"2017","unstructured":"Roehrborn CG, Barkin J, Gange SN (2017) Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. Can J Urol 24:8802\u20138813","journal-title":"Can J Urol"},{"key":"5150_CR3","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1097\/JU.0000000000001073","volume":"204","author":"KT McVary","year":"2020","unstructured":"McVary KT, Kaplan SA (2020) A Tower of Babel in today\u2019s urology: disagreement in concepts and definitions of lower urinary tract symptoms\/benign prostatic hyperplasia re-treatment. J Urol 204:213\u2013214. https:\/\/doi.org\/10.1097\/JU.0000000000001073","journal-title":"J Urol"},{"key":"5150_CR4","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1089\/end.2021.0351","volume":"36","author":"A Das","year":"2022","unstructured":"Das A, Han TM, Rudnick B (2022) Holmium laser enucleation of the prostate following previous prostatic urethral lift. J Endourol 36:111\u2013116. https:\/\/doi.org\/10.1089\/end.2021.0351","journal-title":"J Endourol"},{"key":"5150_CR5","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.8334","author":"NS Dean","year":"2023","unstructured":"Dean NS, Assmus MA, Lee MS, Guo JN, Krambeck AE (2023) Benign prostatic hyperplasia surgical re-treatment after prostatic urethral lift: a narrative review. Can Urol Assoc J. https:\/\/doi.org\/10.5489\/cuaj.8334","journal-title":"Can Urol Assoc J"},{"key":"5150_CR6","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1097\/JU.0000000000001132","volume":"204","author":"LE Miller","year":"2020","unstructured":"Miller LE, Chughtai B, Dornbier RA (2020) Surgical reintervention rate after prostatic urethral lift: systematic review and meta-analysis involving over 2,000 patients. J Urol 204:1019\u20131026. https:\/\/doi.org\/10.1097\/JU.0000000000001132","journal-title":"J Urol"},{"key":"5150_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2019.06.027","author":"KA Parikh","year":"2019","unstructured":"Parikh KA, Dora CD (2019) Holmium laser enucleation of the prostate after failed UroLift: surgical considerations for the management of nonabsorbable implants. Urology. https:\/\/doi.org\/10.1016\/j.urology.2019.06.027","journal-title":"Urology"},{"key":"5150_CR8","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1177\/03915603231180016","volume":"90","author":"P Juliebo-Jones","year":"2023","unstructured":"Juliebo-Jones P, Somani BK, Tzelves L (2023) Complications and device failures associated with Urolift: findings from the MAUDE database. Urologia 90:636\u2013641. https:\/\/doi.org\/10.1177\/03915603231180016","journal-title":"Urologia"},{"key":"5150_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-025-04704-x","author":"K McVary","year":"2025","unstructured":"McVary K, Long B, Cheema A (2025) Comparing complications of Rezum and Urolift for BPH\/LUTS using the Accordion Severity Grading System. Int Urol Nephrol. https:\/\/doi.org\/10.1007\/s11255-025-04704-x","journal-title":"Int Urol Nephrol"},{"key":"5150_CR10","doi-asserted-by":"publisher","DOI":"10.1089\/end.2023.0074","author":"M Huang","year":"2023","unstructured":"Huang M, Dean NS, Assmus MA, Lee MS, Guo J, Krambeck AE (2023) Intradetrusor OnabotulinumtoxinA injections at the time of Holmium laser enucleation of the prostate (HoLEP) for men with overactive bladder symptoms. J Endourol. https:\/\/doi.org\/10.1089\/end.2023.0074","journal-title":"J Endourol"},{"key":"5150_CR11","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/luts.12438","volume":"14","author":"CH Tsai","year":"2022","unstructured":"Tsai CH, Fan YH, Lin ATL (2022) Risk factors for pharmacotherapy for storage symptoms after transurethral resection of the prostate in patients with benign prostatic hyperplasia. Low Urin Tract Symptoms 14:329\u2013333. https:\/\/doi.org\/10.1111\/luts.12438","journal-title":"Low Urin Tract Symptoms"},{"key":"5150_CR12","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1089\/end.2020.0848","volume":"35","author":"P Chialastri","year":"2021","unstructured":"Chialastri P, Chialastri A, Mueller T (2021) Does Prostatic Urethral Lift reduce urinary medications? Trends in medical treatment before and after Prostatic Urethral Lift. J Endourol 35:657\u2013662. https:\/\/doi.org\/10.1089\/end.2020.0848","journal-title":"J Endourol"},{"key":"5150_CR13","first-page":"81","volume":"67","author":"G Comeri","year":"1995","unstructured":"Comeri G, Conti G, Cretarola E (1995) Role of urodynamics in implantation of prostatic stents. Arch Ital Urol Androl 67:81\u201385","journal-title":"Arch Ital Urol Androl"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-026-05150-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-026-05150-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-026-05150-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T07:52:58Z","timestamp":1789631578000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-026-05150-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":13,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["5150"],"URL":"https:\/\/doi.org\/10.1007\/s11255-026-05150-z","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,4]]},"assertion":[{"value":"5 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Amy Krambeck is a consultant for Storz, Wolf, and Boston Scientific.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors did not use generative AI or AI-assisted technologies in the development of this manuscript.","order":2,"name":"Ethics","label":"Declaration of Generative AI and AI-assisted technologies in the writing process","group":{"name":"EthicsHeading","label":"Declarations"}}]}}